-
Je něco špatně v tomto záznamu ?
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia
FJ. Vojdeman, SEM. Herman, N. Kirkby, A. Wiestner, MB. van T' Veer, GE. Tjønnfjord, MA. Itälä-Remes, E. Kimby, MZ. Farooqui, A. Polliack, KL. Wu, JK. Doorduijn, WG. Alemayehu, S. Wittebol, T. Kozak, J. Walewski, MCJ. Abrahamse-Testroote, MHJ. van...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
ZIA HL002346-13
Intramural NIH HHS - United States
- MeSH
- antigen CD52 * krev MeSH
- chronická lymfatická leukemie * krev farmakoterapie imunologie MeSH
- lidé MeSH
- prognóza MeSH
- protinádorové látky terapeutické užití MeSH
- pyrazoly terapeutické užití MeSH
- pyrimidiny terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.
Department of Hematology Rigshospitalet Copenhagen Denmark
Department of Microbiology Rigshospitalet Copenhagen Denmark
e Department of Hematology Leiden University Medical Centre Leiden The Netherlands
g Department of Hematology Turku Central University Hospital Turku Finland
h Division of Hematology Department of Medicine at Huddinge Karolinska Institute Stockholm Sweden
j Department of Hematology Stuivenberg Hospital Antwerpen Belgium
k Department of Hematology Erasmus MC Cancer Center Rotterdam The Netherlands
l HOVON Data Centre Erasmus MC Rotterdam The Netherlands
m Department of Internal Medicine Gelderse Vallei Hospital Amersfoort The Netherlands
p Department of Hematology Academisch Medisch Centrum Amsterdam The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028802
- 003
- CZ-PrNML
- 005
- 20190819115137.0
- 007
- ta
- 008
- 190813s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2017.1285027 $2 doi
- 035 __
- $a (PubMed)28278728
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vojdeman, Fie J $u a Department of Hematology , Rigshospitalet , Copenhagen , Denmark. b Department of Clinical Biochemistry , Bispebjerg-Frederiksberg Hospital , Copenhagen , Denmark.
- 245 10
- $a Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia / $c FJ. Vojdeman, SEM. Herman, N. Kirkby, A. Wiestner, MB. van T' Veer, GE. Tjønnfjord, MA. Itälä-Remes, E. Kimby, MZ. Farooqui, A. Polliack, KL. Wu, JK. Doorduijn, WG. Alemayehu, S. Wittebol, T. Kozak, J. Walewski, MCJ. Abrahamse-Testroote, MHJ. van Oers, CH. Geisler, CU. Niemann,
- 520 9_
- $a CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 12
- $a antigen CD52 $x krev $7 D000074301
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická lymfatická leukemie $x krev $x farmakoterapie $x imunologie $7 D015451
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a pyrazoly $x terapeutické užití $7 D011720
- 650 _2
- $a pyrimidiny $x terapeutické užití $7 D011743
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Herman, Sarah E M $u c Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.
- 700 1_
- $a Kirkby, Nikolai $u d Department of Microbiology , Rigshospitalet , Copenhagen , Denmark.
- 700 1_
- $a Wiestner, Adrian $u c Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.
- 700 1_
- $a van T' Veer, Mars B $u e Department of Hematology , Leiden University Medical Centre , Leiden , The Netherlands.
- 700 1_
- $a Tjønnfjord, Geir E $u f Department of Hematology , Oslo University Hospital and Institute of Clinical Medicine, University of Oslo , Oslo , Norway.
- 700 1_
- $a Itälä-Remes, Maija A $u g Department of Hematology , Turku Central University Hospital , Turku , Finland.
- 700 1_
- $a Kimby, Eva $u h Division of Hematology, Department of Medicine at Huddinge , Karolinska Institute , Stockholm , Sweden.
- 700 1_
- $a Farooqui, Mohammed Z $u c Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.
- 700 1_
- $a Polliack, Aaron $u i Department of Hematology , Hadassah University Hospital, Hebrew University Medical School , Jerusalem , Israel.
- 700 1_
- $a Wu, Ka Lung $u j Department of Hematology , Stuivenberg Hospital , Antwerpen , Belgium.
- 700 1_
- $a Doorduijn, Jeanette K $u k Department of Hematology , Erasmus MC Cancer Center , Rotterdam , The Netherlands.
- 700 1_
- $a Alemayehu, Wendimagegn G $u l HOVON Data Centre, Erasmus MC , Rotterdam , The Netherlands.
- 700 1_
- $a Wittebol, Shulamiet $u m Department of Internal Medicine , Gelderse Vallei Hospital , Amersfoort , The Netherlands.
- 700 1_
- $a Kozak, Tomas $u n Department of Clinical Hematology, Third Faculty of Medicine , Charles University Hospital Kralovske Vinohrady , Prague , Czech Republic.
- 700 1_
- $a Walewski, Jan $u o Lymphoid Malignancies , Maria Sklodowska - Curie Memorial Institute and Oncology Centre , Warszawa , Poland.
- 700 1_
- $a Abrahamse-Testroote, Martine C J $u l HOVON Data Centre, Erasmus MC , Rotterdam , The Netherlands.
- 700 1_
- $a van Oers, Marinus H J $u p Department of Hematology , Academisch Medisch Centrum , Amsterdam , The Netherlands.
- 700 1_
- $a Geisler, Christian H $u a Department of Hematology , Rigshospitalet , Copenhagen , Denmark.
- 700 1_
- $a Niemann, Carsten U $u a Department of Hematology , Rigshospitalet , Copenhagen , Denmark.
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 58, č. 10 (2017), s. 2356-2362
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28278728 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819115411 $b ABA008
- 999 __
- $a ok $b bmc $g 1433951 $s 1067262
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 58 $c 10 $d 2356-2362 $e 20170207 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- GRA __
- $a ZIA HL002346-13 $p Intramural NIH HHS $2 United States
- LZP __
- $a Pubmed-20190813
